LIVIVO - Search results -

Search results

Result 1 - 9 of total 9

Search options

Article ; Online: Discovery of a selective c-MET inhibitor with a novel binding mode.

Collie, Gavin W / Barlind, Louise / Bazzaz, Sana / Börjesson, Ulf / Dale, Ian L / Disch, Jeremy S / Habeshian, Sevan / Jetson, Rachael / Khurana, Puneet / Madin, Andrew / Michaelides, Iacovos N / Peng, Ling / Snijder, Arjan / Stubbs, Christopher J

Bioorganic & medicinal chemistry letters

2022 Volume 75, Page(s) 128948

Abstract: The c-MET receptor tyrosine kinase has received considerable attention as a cancer drug target yet there remains a need for inhibitors which are selective for c-MET and able to target emerging drug-resistant mutants. We report here the discovery, by ... ...

Abstract	The c-MET receptor tyrosine kinase has received considerable attention as a cancer drug target yet there remains a need for inhibitors which are selective for c-MET and able to target emerging drug-resistant mutants. We report here the discovery, by screening a DNA-encoded chemical library, of a highly selective c-MET inhibitor which was shown by X-ray crystallography to bind to the kinase in an unprecedented manner. These results represent a novel mode of inhibiting c-MET with a small molecule and may provide a route to targeting drug-resistant forms of the kinase whilst avoiding potential toxicity issues associated with broad kinome inhibition.
MeSH term(s)	Antineoplastic Agents/pharmacology ; Cell Line, Tumor ; DNA ; Protein Kinase Inhibitors/chemistry ; Proto-Oncogene Proteins c-met ; Small Molecule Libraries/chemistry
Chemical Substances	Antineoplastic Agents ; Protein Kinase Inhibitors ; Small Molecule Libraries ; DNA (9007-49-2) ; Proto-Oncogene Proteins c-met (EC 2.7.10.1)
Language	English
Publishing date	2022-08-17
Publishing country	England
Document type	Journal Article
ZDB-ID	1063195-1
ISSN	1464-3405 ; 0960-894X
ISSN (online)	1464-3405
ISSN	0960-894X
DOI	10.1016/j.bmcl.2022.128948
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3203: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice.

Bartesaghi, Stefano / Wallenius, Kristina / Hovdal, Daniel / Liljeblad, Mathias / Wallin, Simonetta / Dekker, Niek / Barlind, Louise / Davies, Nigel / Seeliger, Frank / Winzell, Maria Sörhede / Patel, Sima / Theisen, Matt / Brito, Luis / Bergenhem, Nils / Andersson, Shalini / Peng, Xiao-Rong

Molecular therapy. Nucleic acids

2022 Volume 28, Page(s) 500–513

Abstract: Fibroblast growth factor 21 (FGF21) is a promising therapeutic agent for treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH). We show that therapeutic levels of FGF21 were achieved following subcutaneous (s.c.) administration of ... ...

Abstract	Fibroblast growth factor 21 (FGF21) is a promising therapeutic agent for treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH). We show that therapeutic levels of FGF21 were achieved following subcutaneous (s.c.) administration of mRNA encoding human FGF21 proteins. The efficacy of mRNA was assessed following 2-weeks repeated s.c. dosing in diet-induced obese (DIO), mice which resulted in marked decreases in body weight, plasma insulin levels, and hepatic steatosis. Pharmacokinetic/pharmacodynamic (PK/PD) modelling of several studies in both lean and DIO mice showed that mRNA encoding human proteins provided improved therapeutic coverage over recombinant dosed proteins
Language	English
Publishing date	2022-04-18
Publishing country	United States
Document type	Journal Article
ZDB-ID	2662631-7
ISSN	2162-2531
ISSN	2162-2531
DOI	10.1016/j.omtn.2022.04.010
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis.

Liu, Cong / Schönke, Milena / Zhou, Enchen / Li, Zhuang / Kooijman, Sander / Boon, Mariëtte R / Larsson, Mikael / Wallenius, Kristina / Dekker, Niek / Barlind, Louise / Peng, Xiao-Rong / Wang, Yanan / Rensen, Patrick C N

Cardiovascular research

2021 Volume 118, Issue 2, Page(s) 489–502

Abstract: Aims: Fibroblast growth factor (FGF) 21, a key regulator of energy metabolism, is currently evaluated in humans for treatment of type 2 diabetes and non-alcoholic steatohepatitis. However, the effects of FGF21 on cardiovascular benefit, particularly on ... ...

Abstract	Aims: Fibroblast growth factor (FGF) 21, a key regulator of energy metabolism, is currently evaluated in humans for treatment of type 2 diabetes and non-alcoholic steatohepatitis. However, the effects of FGF21 on cardiovascular benefit, particularly on lipoprotein metabolism in relation to atherogenesis, remain elusive. Methods and results: Here, the role of FGF21 in lipoprotein metabolism in relation to atherosclerosis development was investigated by pharmacological administration of a half-life extended recombinant FGF21 protein to hypercholesterolaemic APOE3-Leiden.CETP mice, a well-established model mimicking atherosclerosis initiation and development in humans. FGF21 reduced plasma total cholesterol, explained by a reduction in non-HDL-cholesterol. Mechanistically, FGF21 promoted brown adipose tissue (BAT) activation and white adipose tissue (WAT) browning, thereby enhancing the selective uptake of fatty acids from triglyceride-rich lipoproteins into BAT and into browned WAT, consequently accelerating the clearance of the cholesterol-enriched remnants by the liver. In addition, FGF21 reduced body fat, ameliorated glucose tolerance and markedly reduced hepatic steatosis, related to up-regulated hepatic expression of genes involved in fatty acid oxidation and increased hepatic VLDL-triglyceride secretion. Ultimately, FGF21 largely decreased atherosclerotic lesion area, which was mainly explained by the reduction in non-HDL-cholesterol as shown by linear regression analysis, decreased lesion severity, and increased atherosclerotic plaque stability index. Conclusion:* FGF21 improves hypercholesterolaemia by accelerating triglyceride-rich lipoprotein turnover as a result of activating BAT and browning of WAT, thereby reducing atherosclerotic lesion severity and increasing atherosclerotic lesion stability index. We have thus provided additional support for the clinical use of FGF21 in the treatment of atherosclerotic cardiovascular disease.
MeSH term(s)	Adipose Tissue, Brown/drug effects ; Adipose Tissue, Brown/metabolism ; Adipose Tissue, Brown/pathology ; Adipose Tissue, White/drug effects ; Adipose Tissue, White/metabolism ; Adipose Tissue, White/pathology ; Adiposity/drug effects ; Animals ; Anticholesteremic Agents/pharmacology ; Apolipoprotein E3/genetics ; Apolipoprotein E3/metabolism ; Atherosclerosis/blood ; Atherosclerosis/genetics ; Atherosclerosis/pathology ; Atherosclerosis/prevention & control ; Biomarkers/blood ; Cholesterol/blood ; Disease Models, Animal ; Energy Metabolism/drug effects ; Fibroblast Growth Factors/pharmacology ; Hypercholesterolemia/blood ; Hypercholesterolemia/drug therapy ; Hypercholesterolemia/genetics ; Hypercholesterolemia/pathology ; Lipid Metabolism/drug effects ; Lipoproteins, VLDL/blood ; Liver/drug effects ; Liver/metabolism ; Liver/pathology ; Mice, Transgenic ; Plaque, Atherosclerotic ; Recombinant Proteins/pharmacology ; Triglycerides/blood
Chemical Substances	Anticholesteremic Agents ; Apolipoprotein E3 ; Biomarkers ; Lipoproteins, VLDL ; Recombinant Proteins ; Triglycerides ; apolipoprotein E3 (Leidein) ; fibroblast growth factor 21 ; very low density lipoprotein triglyceride ; Fibroblast Growth Factors (62031-54-3) ; Cholesterol (97C5T2UQ7J)
Language	English
Publishing date	2021-03-10
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80340-6
ISSN	1755-3245 ; 0008-6363
ISSN (online)	1755-3245
ISSN	0008-6363
DOI	10.1093/cvr/cvab076
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 565: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Structural Basis for Targeting the Folded P-Loop Conformation of c-MET.

Collie, Gavin W / Michaelides, Iacovos N / Embrey, Kevin / Stubbs, Christopher J / Börjesson, Ulf / Dale, Ian L / Snijder, Arjan / Barlind, Louise / Song, Kun / Khurana, Puneet / Phillips, Christopher / Storer, R Ian

ACS medicinal chemistry letters

2020 Volume 12, Issue 1, Page(s) 162–167

Abstract: We report here a fragment screen directed toward the c-MET kinase from which we discovered a series of inhibitors able to bind to a rare conformation of the protein in which the P-loop adopts a collapsed, or folded, arrangement. Preliminary SAR ... ...

Abstract	We report here a fragment screen directed toward the c-MET kinase from which we discovered a series of inhibitors able to bind to a rare conformation of the protein in which the P-loop adopts a collapsed, or folded, arrangement. Preliminary SAR exploration led to an inhibitor (
Language	English
Publishing date	2020-12-08
Publishing country	United States
Document type	Journal Article
ISSN	1948-5875
ISSN	1948-5875
DOI	10.1021/acsmedchemlett.0c00392
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Fragment-Based Discovery of Novel Allosteric MEK1 Binders.

Di Fruscia, Paolo / Edfeldt, Fredrik / Shamovsky, Igor / Collie, Gavin W / Aagaard, Anna / Barlind, Louise / Börjesson, Ulf / Hansson, Eva L / Lewis, Richard J / Nilsson, Magnus K / Öster, Linda / Pemberton, Josefine / Ripa, Lena / Storer, R Ian / Käck, Helena

ACS medicinal chemistry letters

2021 Volume 12, Issue 2, Page(s) 302–308

Abstract: The MEK1 kinase plays a critical role in key cellular processes, and as such, its dysfunction is strongly linked to several human diseases, particularly cancer. MEK1 has consequently received considerable attention as a drug target, and a significant ... ...

Abstract	The MEK1 kinase plays a critical role in key cellular processes, and as such, its dysfunction is strongly linked to several human diseases, particularly cancer. MEK1 has consequently received considerable attention as a drug target, and a significant number of small-molecule inhibitors of this kinase have been reported. The majority of these inhibitors target an allosteric pocket proximal to the ATP binding site which has proven to be highly druggable, with four allosteric MEK1 inhibitors approved to date. Despite the significant attention that the MEK1 allosteric site has received, chemotypes which have been shown structurally to bind to this site are limited. With the aim of discovering novel allosteric MEK1 inhibitors using a fragment-based approach, we report here a screening method which resulted in the discovery of multiple allosteric MEK1 binders, one series of which was optimized to sub-μM affinity for MEK1 with promising physicochemical and ADMET properties.
Language	English
Publishing date	2021-01-27
Publishing country	United States
Document type	Journal Article
ISSN	1948-5875
ISSN	1948-5875
DOI	10.1021/acsmedchemlett.0c00563
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor.

Michaelides, Iacovos N / Collie, Gavin W / Börjesson, Ulf / Vasalou, Christina / Alkhatib, Omar / Barlind, Louise / Cheung, Tony / Dale, Ian L / Embrey, Kevin J / Hennessy, Edward J / Khurana, Puneet / Koh, Cheryl M / Lamb, Michelle L / Liu, Jianming / Moss, Thomas A / O'Neill, Daniel J / Phillips, Christopher / Shaw, Joseph / Snijder, Arjan /

Storer, R Ian / Stubbs, Christopher J / Han, Fujin / Li, Chengzhi / Qiao, Jingchuan / Sun, Dong-Qing / Wang, Jingwen / Wang, Peng / Yang, Wenzhen

Journal of medicinal chemistry

2023 Volume 66, Issue 13, Page(s) 8782–8807

Abstract: Recent clinical reports have highlighted the need for wild-type (WT) and mutant dual inhibitors of c-MET kinase for the treatment of cancer. We report herein a novel chemical series of ATP competitive type-III inhibitors of WT and D1228V mutant c-MET. ... ...

Abstract	Recent clinical reports have highlighted the need for wild-type (WT) and mutant dual inhibitors of c-MET kinase for the treatment of cancer. We report herein a novel chemical series of ATP competitive type-III inhibitors of WT and D1228V mutant c-MET. Using a combination of structure-based drug design and computational analyses, ligand
MeSH term(s)	Rats ; Animals ; Protein Kinase Inhibitors/pharmacology ; Proto-Oncogene Proteins c-met ; Neoplasms ; Drug Design ; Adenosine Triphosphate ; Antineoplastic Agents/pharmacology
Chemical Substances	Protein Kinase Inhibitors ; Proto-Oncogene Proteins c-met (EC 2.7.10.1) ; Adenosine Triphosphate (8L70Q75FXE) ; Antineoplastic Agents
Language	English
Publishing date	2023-06-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	218133-2
ISSN	1520-4804 ; 0022-2623
ISSN (online)	1520-4804
ISSN	0022-2623
DOI	10.1021/acs.jmedchem.3c00401
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 151: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MB 1: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors.

Collie, Gavin W / Koh, Cheryl M / O'Neill, Daniel J / Stubbs, Christopher J / Khurana, Puneet / Eddershaw, Alice / Snijder, Arjan / Mauritzson, Fredrik / Barlind, Louise / Dale, Ian L / Shaw, Joseph / Phillips, Christopher / Hennessy, Edward J / Cheung, Tony / Narvaez, Ana J

ACS medicinal chemistry letters

2019 Volume 10, Issue 9, Page(s) 1322–1327

Abstract: Many small molecule inhibitors of the cMET receptor tyrosine kinase have been evaluated in clinical trials for the treatment of cancer and resistance-conferring mutations of cMET are beginning to be reported for a number of such compounds. There is now a ...

Abstract	Many small molecule inhibitors of the cMET receptor tyrosine kinase have been evaluated in clinical trials for the treatment of cancer and resistance-conferring mutations of cMET are beginning to be reported for a number of such compounds. There is now a need to understand specific cMET mutations at the molecular level, particularly concerning small molecule recognition. Toward this end, we report here the first crystal structures of the recent clinically observed resistance-conferring D1228V cMET mutant in complex with small molecule inhibitors, along with a crystal structure of wild-type cMET bound by the clinical compound savolitinib and supporting cellular, biochemical, and biophysical data. Our findings indicate that the D1228V alteration induces conformational changes in the kinase, which could have implications for small molecule inhibitor design. The data we report here increases our molecular understanding of the D1228V cMET mutation and provides insight for future inhibitor design.
Language	English
Publishing date	2019-08-02
Publishing country	United States
Document type	Journal Article
ISSN	1948-5875
ISSN	1948-5875
DOI	10.1021/acsmedchemlett.9b00276
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: The Structure of Murine N1-Acetylspermine Oxidase Reveals Molecular Details of Vertebrate Polyamine Catabolism

SjoÌgren, Tove / Aagaard Anna / Barlind Louise / FjellstroÌm Ola / Kaminski Tim P / Kashima Akiko / Kumanomidou Taichi / Snijder Arjan / Wassvik Carola M / Yokota Takehiro

Biochemistry. 2017 Jan. 24, v. 56, no. 3

2017

Abstract: NÂ¹-Acetylspermine oxidase (APAO) catalyzes the conversion of NÂ¹-acetylspermine or NÂ¹-acetylspermidine to spermidine or putrescine, respectively, with concomitant formation of N-acetyl-3-aminopropanal and hydrogen peroxide. Here we present the ... ...

Abstract	NÂ¹-Acetylspermine oxidase (APAO) catalyzes the conversion of NÂ¹-acetylspermine or NÂ¹-acetylspermidine to spermidine or putrescine, respectively, with concomitant formation of N-acetyl-3-aminopropanal and hydrogen peroxide. Here we present the structure of murine APAO in its oxidized holo form and in complex with substrate. The structures provide a basis for understanding molecular details of substrate interaction in vertebrate APAO, highlighting a key role for an asparagine residue in coordinating the NÂ¹-acetyl group of the substrate. We applied computational methods to the crystal structures to rationalize previous observations with regard to the substrate charge state. The analysis suggests that APAO features an active site ideally suited for binding of charged polyamines. We also reveal the structure of APAO in complex with the irreversible inhibitor MDL72527. In addition to the covalent adduct, a second MDL72527 molecule is bound in the active site. Binding of MDL72527 is accompanied by altered conformations in the APAO backbone. On the basis of structures of APAO, we discuss the potential for development of specific inhibitors.
Keywords	active sites ; asparagine ; crystal structure ; hydrogen peroxide ; metabolism ; mice ; putrescine ; spermidine
Language	English
Dates of publication	2017-0124
Size	p. 458-467.
Publishing place	American Chemical Society
Document type	Article
ZDB-ID	1108-3
ISSN	1520-4995 ; 0006-2960
ISSN (online)	1520-4995
ISSN	0006-2960
DOI	10.1021%2Facs.biochem.6b01140
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 217: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The Structure of Murine N

Sjögren, Tove / Wassvik, Carola M / Snijder, Arjan / Aagaard, Anna / Kumanomidou, Taichi / Barlind, Louise / Kaminski, Tim P / Kashima, Akiko / Yokota, Takehiro / Fjellström, Ola

Biochemistry

2017 Volume 56, Issue 3, Page(s) 458–467

Abstract: ... ...

Abstract	N
MeSH term(s)	Aldehydes/chemistry ; Aldehydes/metabolism ; Animals ; Catalytic Domain ; Gene Expression ; Hydrogen Peroxide/chemistry ; Hydrogen Peroxide/metabolism ; Kinetics ; Mice ; Models, Molecular ; Oxidation-Reduction ; Oxidoreductases/chemistry ; Oxidoreductases/genetics ; Oxidoreductases/metabolism ; Propylamines/chemistry ; Propylamines/metabolism ; Protein Structure, Secondary ; Putrescine/analogs & derivatives ; Putrescine/chemistry ; Putrescine/metabolism ; Spermidine/analogs & derivatives ; Spermidine/chemistry ; Spermidine/metabolism ; Spermine/analogs & derivatives ; Spermine/chemistry ; Spermine/metabolism
Chemical Substances	Aldehydes ; Propylamines ; N(1)-acetylspermidine (14278-49-0) ; MDL 72527 (1YVR349GN4) ; N'-acetylspermine (25593-72-0) ; Spermine (2FZ7Y3VOQX) ; Hydrogen Peroxide (BBX060AN9V) ; Oxidoreductases (EC 1.-) ; Spermidine (U87FK77H25) ; Putrescine (V10TVZ52E4)
Language	English
Publishing date	2017-01-24
Publishing country	United States
Document type	Journal Article
ZDB-ID	1108-3
ISSN	1520-4995 ; 0006-2960
ISSN (online)	1520-4995
ISSN	0006-2960
DOI	10.1021/acs.biochem.6b01140
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 217: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito